Informations:
Erreur:
ID
33074
Description
Study ID: 104020 Clinical Study ID: 104020 Study Title: Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00126997 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Combined Measles, Mumps, Rubella, Varicella Vaccine Trade Name: Priorix Tetra Study Indication: Measles; Mumps; Rubella; Varicella CRF Seiten: 268-336; 870-938
Mots-clés
Versions (2)
- 22/11/2018 22/11/2018 -
- 26/11/2018 26/11/2018 -
Détendeur de droits
GSK group of companies
Téléchargé le
26 novembre 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Immunogenicity of Combined Measles Mumps Rubella Varicella Vaccine for healthy 2 y.o children - 104020
Similar models
Eligibility Criteria
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
CL Item
Visit 1 (1)
Date of Visit
Item
Date of Visit
date
Subject Number
Item
Subject Number
integer
Did the subject meet all the entry criteria?
Item
Did the subject meet all the entry criteria?
boolean
If No, tick all boxes corresponding to violations of any exclusion/inclusion criteria.
Item
If No, tick all boxes corresponding to violations of any exclusion/inclusion criteria
text
Item
Tick the boxes corresponding to any of the inclusion criteria the subject failed
text
Code List
Tick the boxes corresponding to any of the inclusion criteria the subject failed
CL Item
Subject who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study (1)
CL Item
Male or female subject between 11 and 21 months of age at the time of the first vaccination (2)
CL Item
Written informed consent obtained from the parent or guardian of the subject (3)
CL Item
Free of obvious health problems as established by medical history and clinical examination before entering into the study (4)
Record if any of the exclusion criteria disqualified the subject from entry
Item
Record if any of the exclusion criteria disqualified the subject from entry
text
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
boolean
Chronic administration (more than 14 days) of immunodepressants or other immune-modifying drugs within six months prior to the first vaccine dose
Item
Chronic administration (more than 14 days) of immunodepressants or other immune-modifying drugs within six months prior to the first vaccine dose
boolean
Planned administration/administration of a vaccine not forseen by the study protocol from 30 days prior to the first vaccination until study end (Week 12)
Item
Planned administration/administration of a vaccine not forseen by the study protocol from 30 days prior to the first vaccination until study end (Week 12)
boolean
Previous vaccination against measles, mumps, rubella and/or varicella
Item
Previous vaccination against measles, mumps, rubella and/or varicella
boolean
History of measles, mumps, rubella and/or varicella/zoster diseases
Item
History of measles, mumps, rubella and/or varicella/zoster diseases
boolean
Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the present trial
Item
Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior to the start of the present trial
boolean
Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection
Item
Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection
boolean
A family history of congenital or hereditary immunodeficiency
Item
A family history of congenital or hereditary immunodeficiency
boolean
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
Item
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
boolean
Major congenital defects or serious chronic illness
Item
Major congenital defects or serious chronic illness
boolean
History of any neurologic disorders or seizures
Item
History of any neurologic disorders or seizures
boolean
Residence in the same household as high-risk persons
Item
Residence in the same household as high-risk persons
boolean
Acute disease at the time of enrolment
Item
Acute disease at the time of enrolment
boolean
Rectal temperature >= 38°C or axillary temperature >=37.5°C at the time of vaccination
Item
Rectal temperature >= 38°C or axillary temperature >=37.5°C at the time of vaccination
boolean
Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period
Item
Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period
boolean
Aucun commentaire